NO20015413D0 - Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser - Google Patents

Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser

Info

Publication number
NO20015413D0
NO20015413D0 NO20015413A NO20015413A NO20015413D0 NO 20015413 D0 NO20015413 D0 NO 20015413D0 NO 20015413 A NO20015413 A NO 20015413A NO 20015413 A NO20015413 A NO 20015413A NO 20015413 D0 NO20015413 D0 NO 20015413D0
Authority
NO
Norway
Prior art keywords
dopamine
medicaments
manufacture
receptor ligands
treatment
Prior art date
Application number
NO20015413A
Other languages
English (en)
Other versions
NO329325B1 (no
NO20015413L (no
Inventor
Bernd Muehlbauer
Gerhard Gross
Dorothea Starck
Hans-Joerg Treiber
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20015413D0 publication Critical patent/NO20015413D0/no
Publication of NO20015413L publication Critical patent/NO20015413L/no
Publication of NO329325B1 publication Critical patent/NO329325B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20015413A 1999-05-07 2001-11-06 Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser og diabetisk nefropati. NO329325B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
PCT/EP2000/003865 WO2000067847A2 (de) 1999-05-07 2000-04-28 Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen

Publications (3)

Publication Number Publication Date
NO20015413D0 true NO20015413D0 (no) 2001-11-06
NO20015413L NO20015413L (no) 2001-11-15
NO329325B1 NO329325B1 (no) 2010-09-27

Family

ID=7908194

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015413A NO329325B1 (no) 1999-05-07 2001-11-06 Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser og diabetisk nefropati.

Country Status (19)

Country Link
US (2) US7098214B1 (no)
EP (1) EP1176963B1 (no)
JP (3) JP4727822B2 (no)
KR (2) KR100781828B1 (no)
CN (2) CN101524356A (no)
AT (1) ATE284693T1 (no)
AU (1) AU770671B2 (no)
BR (1) BR0010337A (no)
CA (1) CA2368823C (no)
CZ (1) CZ301832B6 (no)
DE (2) DE19922443A1 (no)
DK (1) DK1176963T3 (no)
ES (1) ES2234597T3 (no)
HU (1) HU228516B1 (no)
IL (2) IL146232A0 (no)
NO (1) NO329325B1 (no)
PT (1) PT1176963E (no)
WO (1) WO2000067847A2 (no)
ZA (1) ZA200110044B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
JP2003510359A (ja) * 1999-10-01 2003-03-18 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
IL157412A0 (en) * 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
MXPA03006843A (es) * 2001-02-16 2003-11-13 Aventis Pharma Inc Derivados heterociclicos novedosos de ureas y su uso como ligandos para receptor d3 de dopamina.
EP1935887B1 (en) 2001-02-16 2010-01-13 Aventis Pharmaceuticals, Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
JP2005516604A (ja) 2002-02-04 2005-06-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １３１、１４８、１９９、１２３０３、１３９０６、１５５１３、１７８２２、３０２、５６７７、１９４、１４３９３、２８０５９、７３６６、１２２１２、１９８１、２６１、１２４１６、２７０、１４１０、１３７、１８７１、１３０５１、１８４７、１８４９、１５４０２、３４０、１０２１７、８３７、１７６１、８９９０または１３２４９分子を用いて血液障害を処置するための方法および組成物
WO2004082569A2 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
EP1778684B1 (en) * 2004-08-09 2009-12-16 Abbott GmbH & Co. KG 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR
CA2583779C (en) 2004-10-14 2013-12-10 Abbott Gmbh & Co. Kg Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to m0dulation of the dopamine d3 receptor
BRPI0515998A (pt) 2004-10-14 2008-08-19 Abbott Gmbh & Co Kg compostos heterocìclicos adequados para tratar desordens que respondem à modulação do receptor d3 de dopamina
BRPI0516529A (pt) 2004-10-14 2008-09-09 Abbott Gmbh & Co Kg compostos de 6-amino(aza)indano apropriados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3
EP1809597B1 (en) 2004-10-14 2012-01-11 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
EP2004166A2 (en) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
JPWO2008016171A1 (ja) * 2006-08-04 2009-12-24 味の素株式会社 腎機能障害予防・治療剤
EP2256109A4 (en) * 2008-01-25 2011-06-15 Univ Nihon APOPTOSIS INHIBITOR
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (no) * 1962-12-26
US3290004A (en) * 1965-04-09 1966-12-06 Hitachi Ltd Device for damping vibration of long steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
WO2000067847A3 (de) 2001-08-02
JP2011088941A (ja) 2011-05-06
WO2000067847A2 (de) 2000-11-16
DK1176963T3 (da) 2005-04-25
US20060223793A1 (en) 2006-10-05
KR20070040425A (ko) 2007-04-16
DE19922443A1 (de) 2000-11-09
AU770671B2 (en) 2004-02-26
CA2368823C (en) 2008-10-21
JP5897054B2 (ja) 2016-03-30
ATE284693T1 (de) 2005-01-15
HU228516B1 (en) 2013-03-28
PT1176963E (pt) 2005-05-31
NO329325B1 (no) 2010-09-27
JP5542713B2 (ja) 2014-07-09
EP1176963B1 (de) 2004-12-15
JP2014098044A (ja) 2014-05-29
HUP0202399A2 (hu) 2002-12-28
KR100781828B1 (ko) 2007-12-03
ES2234597T3 (es) 2005-07-01
CA2368823A1 (en) 2000-11-16
CN1360502B (zh) 2010-08-04
JP2002544178A (ja) 2002-12-24
JP4727822B2 (ja) 2011-07-20
IL146232A (en) 2007-06-03
US8785447B2 (en) 2014-07-22
DE50008964D1 (de) 2005-01-20
ZA200110044B (en) 2003-03-06
CZ301832B6 (cs) 2010-07-07
NO20015413L (no) 2001-11-15
EP1176963A2 (de) 2002-02-06
CN1360502A (zh) 2002-07-24
KR20010112474A (ko) 2001-12-20
BR0010337A (pt) 2002-02-13
IL146232A0 (en) 2002-07-25
HUP0202399A3 (en) 2003-02-28
AU4559100A (en) 2000-11-21
CZ20014015A3 (cs) 2002-02-13
CN101524356A (zh) 2009-09-09
US7098214B1 (en) 2006-08-29

Similar Documents

Publication Publication Date Title
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
BG108495A (en) 5-ht receptor ligands and uses thereof
NO20053384L (no) Benzazepinderivater for behandling av neurologiske forstyrrelser.
DE60023141D1 (de) Selektive npy (y5) antagonisten
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
NZ544244A (en) Dual NK1/NK3 antagonists for treating schizophrenia
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
HUP0203338A2 (hu) Integrin receptor ligandumok
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
MXPA06000193A (es) Derivados de imidazol iii.
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
NO20030717D0 (no) Forbindelser for behandling av avhengighetsforstyrrelser
WO2007053352A3 (en) Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
ATE306483T1 (de) Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
SE9802836L (sv) Läkemedel för behandling av schizofreni
NO20014889D0 (no) Fremgangsmåte for fremstilling av medisinske midler

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE

MK1K Patent expired